Glucagon analogues as long-acting GLP-1 / glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

TW202629586APending Publication Date: 2026-07-16BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
BOEHRINGER INGELHEIM INT GMBH
Filing Date
2021-04-23
Publication Date
2026-07-16

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1 / glucagon receptor agonist activity in the prevention and / or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non- alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and / or cirrhosis.
Need to check novelty before this filing date? Find Prior Art